1. Overview
  2. All Stocks
  3. argenx SE

argenx (ARGX.US) Price Target 2026/2027: 35% Upside – Rating and Stock Analysis

846.27
Analysis framework by , founder of TradeDesk · Data: EODHD, insider trades from SEC Form 4 filings · Updated
Share this analysis:

argenx Price Target 2026: Analysts See 36% Upside

The average price target for argenx is $1,152.70. This price target represents the analysts' view of the stock price over the next 12 months. The stock may be undervalued, because the price target is higher than the current price. The stock is 36.21% below the target, which can point to potential returns within the next 12 months if the analysts' view proves right. Also consider the stock's valuation ratios such as P/E, P/S and P/B, plus the technical analysis further down the page, for the full picture.

Is argenx overvalued or undervalued?

argenx is currently undervalued with a gap of 36.2% relative to the price target.


The current price is $846.27, which places argenx in the undervalued category. The stock is considered undervalued when the price is below $1,037.43, and overvalued when the price exceeds $1,267.97.


The fair value range is defined as ±10% of the price target, because price targets are estimates rather than exact values. For argenx, the fair value range lies between $1,037.43 and $1,267.97.


See the full price target analysis for argenx →

↑ Back to navigation

Analyst Ratings for argenx stock in 2026: Buy

25 analysts cover argenx. There is broad agreement on a positive view — 88% recommend buying. The average price target is $1,152.70, which gives an upside of 36.2% from the current price.

Consensus: Buy (4.48/5)
Strong Buy
15 (60%)
Buy
7 (28%)
Hold
3 (12%)
Strong Sell Sell Hold Buy Strong Buy
4.48 out of 5 based on 25 analysts
↑ Back to navigation

About argenx – Biotechnology

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands. Read more about the company

Key Figures for argenx

$50.8B Market cap
$5.3B Revenue
Biotechnology Industry
30.82 P/E
9.57 P/S
7.03 P/B
United States Listed on exchange
argenx.com Website
Healthcare Sector

What kind of stock is argenx?

Growth stock

argenx is classified as a growth stock with quarterly earnings growth of 95.2% and strong long-term momentum of 0.0%.

Score Overview for argenx

💰 Value Score 28/100 (Low)
⭐ Quality Score 82/100 (Very High)
🚀 Momentum Score 51/100 (Neutral)
📊 Total Score 53/100

📈 Valuation

argenx trades at a P/E ratio of 30.8, which is above the market average. The forward P/E is 25.9 (16% lower), which suggests the market expects rising earnings. The P/S ratio is 9.6 (high — the market pays a premium for the revenue). The P/B ratio is 7.0. The PEG ratio is 1.15.

💵 Profitability & Growth

argenx has a profit margin of 32.3% (excellent) and an operating margin of 32.0%. Return on equity (ROE) is 23.6% — excellent return on equity. Return on assets (ROA) is 11.6%. The latest quarterly earnings grew 95.2% year over year — strong growth.

🏦 Financial Health

The Piotroski score is 6 out of 9 — good financial health. Altman Z2 is 11.68 (healthy balance sheet — low risk). The debt-to-equity ratio (D/E) is 12.8% — low debt, a solid balance sheet.

🚀 Momentum & Short Interest

Short interest is 2.16%.

↑ Back to navigation

argenx Short Selling 2026: 2.2% Sold Short

Moderate short interest: 2.2% of the free float
Short % of free float
2.2%
Assessment
Moderate short interest
Short squeeze risk
Low
Data source
EODHD
Reported about twice a month
The stock has a moderate share of short selling. Between 2-5% of the freely traded shares are sold short, which is within the normal range for most stocks.

Short interest comes from our data provider EODHD. The figure is reported about twice a month; we check it every trading day.
Short Interest Scale
0% 2% 5% 10% 20%+
Low Moderate High Very High Extreme
▲
2.2%

↑ Back to navigation

When Does argenx Report Earnings – Next Date: Oct 22, 2026

The next earnings report from argenx is scheduled for October 22, 2026, before the market opens. This report covers the third quarter (Q3), which ended on September 30, 2026.



↑ Back to navigation

Technical Analysis of argenx 2026 – Signal: Sell

Overall Technical Signal: Sell

Based on trend analysis (SMA50/SMA200) and MACD trend (positive/negative on a daily + weekly basis). Updated October 16, 2026.

Trend Analysis of argenx SE

argenx SE is in a short-term downtrend. The price of $846.27 is 7.3% below the 20-day average ($913.09). Medium term, the picture is negative: the price is 11.3% below the 50-day average ($953.99). Long term, the stock is 0.6% below the 200-day average ($851.47), which signals a long-term downtrend.

Golden Cross: The 50-day average (953.99) is above the 200-day average (851.47), which is a classic bullish signal for argenx SE.

Is argenx SE overbought or oversold?

argenx SE has an RSI of 36.4. The stock sits in the lower part of the neutral zone, which points to weak momentum without being oversold. In the current downtrend, be careful about reading this as a buying opportunity.

MACD Analysis for argenx SE

Daily MACD: MACD is negative (-40.949), which means the short-term trend is bearish (the 12-day EMA is below the 26-day EMA). MACD is below the signal line (-29.378) by 11.571, which confirms growing negative momentum in the downtrend.

Weekly MACD: MACD5 is positive (28.316), which indicates a broader bullish long-term trend. MACD5 is below the signal line (41.105) by 12.789, which suggests the long-term momentum is fading – the positive trend could come under pressure.

Overall MACD assessment: The daily and weekly MACD give conflicting signals. The long-term trend is bullish, but the short-term trend is bearish. Short-term momentum is still falling – a deeper pullback is possible.

Risk Profile for argenx SE

argenx SE has an annual standard deviation of 36.6%, which classifies the stock as medium risk. The price can swing noticeably when the market moves.

Overall Technical Conclusion for argenx SE

Trend: Negative. The price trades below SMA50 and SMA200.

MACD trend (zero line): Daily bearish (-40.949). Weekly bullish (28.316).

MACD momentum (signal): Daily falling. Weekly falling.

RSI: 36.4 – neutral.

Technical signal: Sell

The trend is negative and MACD is below the zero line, which confirms the bearish momentum. Consider reducing the position or setting a stop-loss.

↑ Back to navigation

Frequently Asked Questions About argenx stock in 2026

Should you buy argenx stock now?
No, the technical signal for argenx is currently Sell. argenx trades at $846.27 as of Oct 16, 2026. The technical analysis shows the following: MACD is negative (bearish trend) at -40.949 with falling momentum (signal: -29.378); RSI is at 36.4 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $1,152.70 points to 36.2% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for argenx stock?
The average analyst price target for argenx is $1,152.70. The current price is $846.27, which gives an upside of 36.2%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $1,037.43 and $1,267.97.
Is argenx a dividend stock?
No, argenx does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of argenx stock?
argenx is rated as a stock in the risk category Moderate. the annual standard deviation is 36.6%, which classifies the stock as Moderate.
Is argenx overvalued?
No, argenx is considered undervalued based on the analyst price target (36.2% upside). argenx has the following valuation ratios: a P/E ratio of 30.8 (highly valued), a P/S ratio of 9.6, a P/B ratio of 7.0. The analyst price target suggests that the stock is undervalued by 36.2%.
Is argenx overbought?
No, argenx is not overbought. RSI is at 36.4 (neutral zone). The technical indicators show: RSI is at 36.4 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 7.3% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish).
When is the next argenx earnings report?
argenx reports its next earnings on October 22, 2026. The stock currently trades at $846.27. With a P/E ratio of 30.8, the market will be watching closely whether earnings meet expectations.
Is argenx shorted?
Yes, argenx is shorted with 2.2% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying argenx stock?
There is currently no registered insider trading for argenx.
Is argenx a good stock?
Based on our total score, argenx is rated as a mediocre stock with a total score of 53 out of 100. The stock scores around average on value, quality and momentum – it sits near the median in our database. The score is made up of Value: 28/100, Quality: 82/100, Momentum: 51/100. In addition: analysts see 36.2% upside to the price target. Whether now is the time to buy is a separate question: the technical signal is Sell. Whether argenx is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for argenx stock?
The outlook for argenx based on current data: the average analyst price target is $1,152.70 (+36.2%); the stock is in a downtrend (below SMA50 and SMA200); the next earnings report is due on Oct 22, 2026, which can move the price; the P/E ratio is 30.8 (high – the market expects growth). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is argenx stock falling?
argenx is falling right now. The technical indicators show: the price is 7.3% below the 20-day average; MACD is negative with falling momentum (bearish signal). For the latest context, see our technical analysis and insider section above.
How high can argenx go?
The average analyst price target for argenx is $1,152.70, which corresponds to a potential gain of 36.2% from the current price of $846.27. The stock has traded between $661.85 and $1,072.75 over the last 52 weeks. The price is 21.1% below the 52-week high, which can indicate potential if the underlying fundamentals are intact. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can argenx fall?
The stock has traded as low as $661.85 over the last 52 weeks — that is 21.8% below the current price of $846.27. The biggest decline (drawdown) in the same period was 38.3% from high to low. Within a year, the price typically swings about ±36.6% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does argenx do?
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP),... The company belongs to the Healthcare sector, more specifically the Biotechnology industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate argenx as an investment.
Did argenx raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from argenx. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is argenx making money or losing money?
Yes, argenx is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 32.3% — which is excellent. The operating margin (profit before interest and taxes) is 32.0%. At a P/E ratio of 30.8, you currently pay 30.8 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can argenx go bankrupt?
The bankruptcy risk of argenx is rated as low. Altman Z2 (a model for assessing financial distress) is 11.68 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 6 — which is average. Debt relative to equity is 13% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does argenx have a lot of debt?
No, argenx has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 13%. For the healthcare sector, anything below 80% counts as low debt. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can argenx service its debt? Can service its debt without problems — the interest coverage ratio (how many times earnings can cover interest payments) is 423.0x, and the company has more cash than debt (net cash).
↑ Back to navigation

Other Stocks in Healthcare

Compare argenx with other stocks in the healthcare sector. Click a stock to see its technical analysis, insider trading and key figures.

See all 108 stocks in the Healthcare sector

Explore More